Navigation Links
Actonel Treats Hip Fractures In A Better Way Than Alendronate

New study shows that osteoporosis patients treated with Actonel are more likely to sustain when compared to alendronate. //These results were published today in the peer-reviewed journal Osteoporosis International after collecting data from 33,000 women with osteoporosis.

The study of 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel? (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. 'The rapid onset of fracture reduction observed for risedronate in this study is consistent with results from randomised clinical trials of risedronate,' says Professor Pierre Delmas, study author, Universite Claude Bernard, Lyon.

'Earlier fracture protection means that fewer patients will suffer the devastating consequences of an osteoporotic fracture, helping to both preserve patients' quality of life and to reduce the economic burden of healthcare.'

The REAL (RisedronatE, ALendronate) retrospective cohort study included 33,830 women newly treated with once-weekly doses of either Actonel or alendronate in 'real-life' clinical practice. Results showed that at six months patients on Actonel had a 46% (p=0.02) lower incidence of hip fractures compared to patients on alendronate. At 12 months similar results were seen, with Actonel resulting in a 43% (p=0.01) greater reduction in risk of hip fracture versus alendronate. The two treatments were not compared on the basis of side effects in this study.

This study adds to the body of evidence from randomised controlled trials demonstrating that Actonel exerts an early onset of fracture protection, seen as early as six months for clinical vertebral fracture and nonvertebral fractures. No other bisphosphonate treatments for osteoporosis have been shown in clinical trials to reduce clinical fractures this early for pat ients. However, data are limited that compare therapies directly in the same study on the basis of fracture reduction - the clinically important endpoint in osteoporosis treatment.

'In the osteoporosis field it is unlikely that prospective, head-to-head clinical fracture trials will be conducted due to the large number of patients required to show a difference between two effective therapies,' said Professor Delmas. 'Large, comparative, retrospective analyses, like the REAL study, are one way to fill the knowledge gap and should be considered in the total body of evidence for a drug to optimise treatment decisions and enhance patient care.'

Currently 1.6 million hip fractures occur worldwide per year, accounting for approximately €104 billion in worldwide annual healthcare costs. Among those patients who suffer a hip fracture, approximately one in five will die within the following year and 40% will be unable to walk independently one year later.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Cyclosporin A Treats Leukemia Complications
3. Weight Reduction Surgery Also Treats Metabolic Syndrome
4. Chennai Hospital Treats Pakistani Blue Baby
5. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
6. New Gene Therapy Treats Diabetic Neuropathy
7. BBIC – A SOY-based Substance Treats Multiple Sclerosi
8. Cake Walk – Plum Treats Sell Like Hot Cakes During Christma
9. Common BP Drug Treats Muscular Dystrophy
10. Naltrexone also Treats Crohns Disease
11. Drug for Blood Pressure also Treats Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology: